Barinthus Biotherapeutics plc American Depositary Shares (BRNS)

About BRNS

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunother…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

14

Website

www.barinthusbio.com/

Fundamentals

1-day range

$0.7$0.7464

Market cap

$23.08M

P/E (trailing)

—

P/E (forward)

-0.66

EPS (trailing)

$-1.12

Dividend yield

—

Beta

-0.32

Avg. volume

78.4K

Forecasts

1 analyst ratings

Barinthus Biotherapeutics plc American Depositary Shares Competitors

Chosen by industry and closest market cap.

• BRNS

  Barinthus Biotherapeutics plc American Depositary Shares

  $0.7464

  ▲ 2.11%
  Market cap $23.08MP/E —
  $0.512$1.83
• TVRD

  Tvardi Therapeutics Inc. Common Stock

  $1.8

  ▲ 0.00%
  Market cap $23.02MP/E —
  $1.5$43.65
• IGC

  IGC Pharma Inc. Common Stock

  $0.3086

  ▼ 6.48%
  Market cap $23.94MP/E —
  $0.24$0.5
• TXMD

  TherapeuticsMD Inc. Common Stock

  $2.22

  ▼ 0.89%
  Market cap $24.19MP/E —
• CALC

  CalciMedica Inc. Common Stock

  $0.4644

  ▼ 1.19%
  Market cap $21.88MP/E —
  $0.4606$7.2
• LGVN

  Longeveron Inc. Class A Common Stock

  $6.72

  ▼ 1.47%
  Market cap $24.44MP/E —
  $4.75$12.3
• AYTU

  Aytu BioPharma Inc. Common Stock

  $2.27

  ▲ 1.34%
  Market cap $25.01MP/E —
  $1.65$3.07

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
  Yahoo · 8/24/2026
• Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate
  benzinga · 8/6/2026
• Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
  Yahoo · 8/6/2026
• Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate
  Benzinga · 8/6/2026

Institutional Ownership

March 31, 2026

Total shares held

9.30M

Total value held

$7.89M

Institutional holders

14